OT kinda strep/cancer connection | Arthritis Information

Okay, so I do this day stock trading trip against pharmaceuticals as a harmless, and hopefully fruitful revenge against Big Pharma. I have posted over in lupus about one stock and this one is on to a cancer treatment. You can access this link below yourself by going to Yahoo, Finance, ONCY*, messages, entitled More Information from NCR ... by a poster named hellacious. At the bottom of a portion of the abstract is a mention of a strep/cancer connection:

The link won't work :( And if you think this BBS Board is rough, you should check out day trading posts. It's pure shark-infested waters.

You can access this link below yourself by going to Yahoo, Finance, ONCY*, messages, entitled More Information from NCR ... by a poster named hellacious. At the bottom of a portion of the abstract is a mention of a strep/cancer connection.

* DISCLOSURE: I own stocks in ONCY. PS Its stock ticker letters are ONCY not ONCY* :)

GoGo, this is what I should have posted in the first place - end of the excerpt:

NCRI Conference Sept 30 - Oct 03, 2007 Birmingham, UK

In addition to the presentation by Robin Prestwich which was previously discussed here, Kevin Harrington (one of the UK researchers) is also presenting at this conference.

Harrington's presentation is one of several listed under the following section:

Tuesday 2 October 2007

Integration of new molecular therapies with radiation –
Sponsored by The Royal College of Radiologists and The British
Oncological Association

Kevin Harrington
The Institute of Cancer Research, London, UK
Biological approaches to radiosensitisation: viruses, gene
therapy and novel radiosensitisers

Two Prestwich presentations on October 02 are:

As previously posted:
Robin Prestwich
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of
Leeds, UK
Reovirus infection of human melanoma cells supports priming
of anti-tumour cytotoxic T cell immunity – Proffered Paper
Presentation

The second presentation is apparently unrelated to Oncolytics.
o Robin Prestwich
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of
Leeds, UK
Clinical study of intralymphatic delivery of OK432-matured
dendritic cells for activation of innate anti-tumour immunity –
Proffered Paper Presentation
FYI:
"OK432, a heat and penicillin-treated lyophilized powder of the Su-strain of Streptococcus pyogenes, is one of the biological response modifiers (BRMs) developed by Okamoto et al. [1]. Several studies have demonstrated that anti-tumour effects of OK432 may be due to the activation of a variety of effector cells such as macrophages, natural killer (NK) cells, autotumour killer cells and cytotoxic T lymphocytes [2–5]."